Analysts weigh in on Geron after upbeat imetelstat ASH presentation

"While we have advised caution ahead of a peer-reviewed release of the MF data, we can now report that the robustness of these data exceed our expectations," Needham's Chad Messer says, referencing Monday evening's imetelstat data presented by Geron (GERN) at ASH.

Messer says imetelstat "has blockbuster potential as the first treatment with the potential to induce treatment response in MF." GERN upgraded to Buy from Hold. Price target is $10.

Meanwhile, Piper is out with a bullish note as well, as analyst Charles Duncan says the imtelstat data "appears strong in terms of differentiated efficacy."

Duncan has the shares at Overweight. Price target is $10, representing "4X projected 2024 sales of imetelstat in MDS and MF, discounted at 15% to YE13."

For more, see here

GERN +14% premarket

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs